Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Is there any upper limit of volume or shape of a prostate gland which would be a red flag to cytoreduce prior to treatment?
What is the upper limit of size you would consider offering a patient a five fraction regimen?
Answer from: Radiation Oncologist at Community Practice
Astro/aua consensus guidelines based on published data limits to 100cc or less
Comments
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This consensus statement is for SBRT
860
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
No.
Sign In
or
Register
to read more
4362
4375
Related Questions
Do you utilize daily enemas for patients undergoing prostate SBRT?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
When treating an inoperable urothelial cancer of the renal pelvis, what are your considerations when determining candidacy for SBRT?
How would you manage a medically inoperable patient with locally recurrent nest variant muscle invasive urothelial carcinoma s/p radical cystectomy years ago now involving the urethral anastomosis, sphincter and neo-bladder, status post TUR?
How often do you utilize intrafraction motion tracking when treating prostate cancer?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
How do you manage prostatic adenocarcinoma after a subtotal resection?
This consensus statement is for SBRT